A Pilot Study of FFP104 in Subjects With Crohn's Disease
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
This study will be conducted to evaluate the safety, tolerability and efficacy of
intravenously administered FFP104 or placebo over 15 days (3 total doses) in subjects with
moderate to severely active Crohn's Disease